Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

Key facts

Sponsor

University College, London

Principal Investigator

Oren Tomkins-Netzer, MD, PhD

University College, London

Intervention

Simvastatin(drug)

Enrollment

50 target

Eligibility

18-80 years · All sexes

Timeline

2015 – 2019

Study locations (1)

• Moorfields Eye Hospital, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Uveitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06974162
  Metagenomics for Ocular Inflammation
  Moorfields Eye Hospital NHS Foundation Trust
• ACTIVE NOT RECRUITINGNCT06821971
  Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
  Centre Hospitalier Universitaire, Amiens
• RECRUITINGEARLY PHASE1NCT07145008
  Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
  University of Baghdad
• ACTIVE NOT RECRUITINGNANCT06585670
  Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
  University of California, San Francisco
• RECRUITINGPHASE1NCT06161415
  Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
  Quan Dong Nguyen
• ACTIVE NOT RECRUITINGNCT06686641
  Incidence of Macular Edema in a Uveitis Population
  Aalborg University Hospital
• ACTIVE NOT RECRUITINGNANCT06310837
  Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
  Zhongshan Ophthalmic Center, Sun Yat-sen University
• RECRUITINGNCT05727540
  The Cohort Study of Uveitis Patients
  Zhongshan Ophthalmic Center, Sun Yat-sen University

See all trials for Uveitis →